1 month ago
18
Soumya Eswaran
Thu, February 5, 2026 astatine 7:56 AM CST 3 min read
Fidelity Investments, an concern absorption company, precocious released its “Fidelity Growth Strategies Fund” fourth-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The Fidelity Growth Strategy is simply a diversified equity strategy aimed astatine home midcap maturation stocks. The attack focuses connected identifying prime companies that present dependable above-average maturation and tin outperform implicit time. The Fund (Retail Class shares) returned -3.44% successful the 4th compared to the benchmark Russell Midcap® Growth Index’s -3.70% return. In Q4, the U.S. banal marketplace continued its accelerated rebound, driven by robust firm fundamentals and beardown spending connected artificial intelligence. Mid-cap maturation stocks underperformed, portion large-cap stocks gained chiefly from a constrictive radical of companies connected to generative AI, and small-cap equities benefited from involvement complaint sensitivity. As 2026 begins, the steadfast believes the concern cycles successful the U.S. and globally stay positive. The Strategy remains focused connected companies possessing durable competitory advantages and maturation potential. Please reappraisal the Fund’s apical 5 holdings to summation insights into their cardinal selections for 2025.
In its fourth-quarter 2025 capitalist letter, Fidelity Growth Strategies Fund highlighted IDEXX Laboratories, Inc. (NASDAQ:IDXX). IDEXX Laboratories, Inc. (NASDAQ:IDXX) is simply a US-based healthcare institution that manufactures products for the companion carnal veterinary, livestock and poultry, dairy, and h2o investigating industries. On February 4, 2026, IDEXX Laboratories, Inc. (NASDAQ:IDXX) banal closed astatine $642.94 per share. IDEXX Laboratories, Inc. (NASDAQ:IDXX) delivered a -9.75% instrumentality successful the past month, and its shares are up 39.60% implicit the past 12 months. IDEXX Laboratories, Inc. (NASDAQ:IDXX) has a marketplace capitalization of $51.438 billion.
Fidelity Growth Strategies Fund stated the pursuing regarding IDEXX Laboratories, Inc. (NASDAQ:IDXX) successful its 4th fourth 2025 capitalist letter:
"Not holding IDEXX Laboratories, Inc. (NASDAQ:IDXX) (+6%), a shaper of veterinary products and a sizable benchmark component, besides hurt. IDEXX is simply a coagulated and accordant business, and successful its latest quarterly update, reported successful November, it delivered beardown results that materially outperformed expectations. But we don't deliberation the existent maturation is sustainable implicit the longer word and similar different investments successful the mid-cap maturation universe."
IDEXX Laboratories, Inc. (NASDAQ:IDXX) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 55 hedge money portfolios held IDEXX Laboratories, Inc. (NASDAQ:IDXX) astatine the extremity of the 3rd quarter, up from 48 successful the erstwhile quarter. While we admit the imaginable of IDEXX Laboratories, Inc. (NASDAQ:IDXX) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
English (CA) · 
English (US) · 
Spanish (MX) ·